(NASDAQ: FLGT) Fulgent Genetics's forecast annual revenue growth rate of 11.69% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.77%.
Fulgent Genetics's revenue in 2026 is $320,346,000.On average, 4 Wall Street analysts forecast FLGT's revenue for 2026 to be $10,123,970,081, with the lowest FLGT revenue forecast at $9,721,817,259, and the highest FLGT revenue forecast at $10,427,288,734. On average, 4 Wall Street analysts forecast FLGT's revenue for 2027 to be $11,404,270,166, with the lowest FLGT revenue forecast at $10,701,638,753, and the highest FLGT revenue forecast at $12,013,463,529.
In 2028, FLGT is forecast to generate $12,522,118,687 in revenue, with the lowest revenue forecast at $11,784,270,501 and the highest revenue forecast at $13,154,600,561.